Approved for VOYXACT (sibeprenlimab-szsi) is indicated for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression.. Sibeprenlimab is a humanized IgG2 monoclonal antibody that binds to and inhibits A Proliferation-Inducing Ligand (APRIL). APRIL is a cytokine that promotes B-cell survival and IgA class switching.… Side effects, costs,…
Loading full data from Know Your Drugs Institute…